Rossum Robot Completes Series C Financing to Advance Commercialization of World-First Intelligent Orthopedic Solution; WinX Capital Serves as Exclusive Financial Advisor

Recently,Beijing Rossum Robot Technology Co., Ltd. (hereinafter referred to as “Rossum Robot”) has completed its Series C financing round. The round was co-led by the Beijing Robotics Industry Investment Fund and Medtronic China Fund, with participation from the Beijing Pharmaceutical and Health Industry Investment Fund and GTJA Investment Group. WinX Capital served as the exclusive financial advisor. The proceeds will be primarily used to accelerate the commercialization of Rossum Robot’s globally first-of-its-kind intelligent orthopedic solutions, as well as to support the research, development, and iterative improvement of subsequent products.

Rossum Robot, established in 2017, focuses on original innovation in the field of intelligent healthcare, aiming to enhance health and well-being through technological advancement. Since its inception, the company has adhered to a development path “driven by urgent clinical needs and grounded in original, deep cross-disciplinary innovation between medicine and engineering,” firmly believing that “patient benefit is a necessary and sufficient condition for the commercial success of surgical robots.”

Over the past seven years, despite the ever-changing market landscape, Rossum Robot has neither followed trends nor blindly conformed. Instead, it has remained true to its original mission by focusing on closed reduction of pelvic fractures—widely recognized internationally as one of the most challenging procedures in orthopedics. The company has developed the world’s first surgical robot system capable of performing minimally invasive reduction for complex fractures. This strategic focus has not only secured a unique competitive advantage in terms of functionality and product positioning but also established a substantial technological moat. Rossum Robot’s technology and products have garnered high recognition from clinical experts both in China and abroad, as well as strong affirmation and support from numerous professional investors.

Closed reduction of pelvic fractures, widely recognized internationally as the most challenging surgical procedure in trauma orthopedics, has long remained an insurmountable barrier for clinicians and biomedical engineers. The procedure essentially pushes against the limits of human physiology: on one hand, the highly complex three-dimensional anatomy of the pelvis is difficult to fully visualize through intraoperative fluoroscopy, posing a significant challenge to surgeons’ spatial imagination; on the other hand, closed reduction requires precise adjustments of position and orientation under high mechanical loads, yet the human body struggles to simultaneously exert force while accurately controlling speed and displacement—a persistent pain point in clinical practice. Developed countries such as the United States, Japan, and Germany have conducted extensive research and development efforts to address this issue, but no mature system has yet entered clinical application. Consequently, open reduction remains the predominant treatment approach, associated with large incisions, substantial blood loss, and persistently high rates of postoperative complications, representing an urgent clinical problem in need of resolution.

Rossum Robot bravely took on the challenge of solving a complex international problem, driven by the fact that successful development of this product would eliminate the need for major open surgeries in patients with complex fractures, thereby delivering substantial benefits to patients. After three generations of prototype iterations and countless rounds of validation and optimization, the Rossum Wanxiang® Intelligent Orthopedic Surgical Robot System successfully passed the National Medical Products Administration’s (NMPA) innovative product registration application and obtained the Class III medical device registration certificate on December 8, 2023. Rossum Robot has pioneered globally advanced technologies, including real-time intraoperative 3D navigation for fractures, robot-assisted fracture reduction, and intelligent surgical planning, enabling intelligent surgical operations throughout the entire procedure from closed fracture reduction to minimally invasive fixation. To date, the system has been used in over 300 procedures across more than 20 hospitals in 14 provinces, municipalities, and autonomous regions nationwide. The success rate of closed reduction exceeds 98%, with an excellent/good outcome rate greater than 95%, significantly surpassing the performance of manual reduction by experts. Moreover, it substantially reduces radiation exposure to surgeons during procedures, innovatively addressing the practical needs of both physicians and patients.

Meanwhile, Rossum Robot has developed a series of innovative products centered on genuine clinical needs. A prime example of addressing cost challenges through technological innovation is the Rossum Lighthouse® Miniaturized Surgical Robot, an positioning and navigation robot independently developed by Rossum Robot, primarily indicated for trauma and spinal surgeries. On February 21, 2024, the Rossum Lighthouse® Intelligent Miniature Surgical Robot successfully received marketing approval from the National Medical Products Administration (NMPA). Serving as a beacon to guide and safeguard both physicians and patients, this achievement marks another milestone in Rossum Robot’s journey of innovation. It integrates the flexibility and stability of the Rossum Tiangong® Surgical Robotic Arm with the dynamic real-time visual navigation capabilities of the Rossum Wanxiang® Intelligent Orthopedic Surgical Robot. Featuring “precise positioning, compact stability, and flexible convenience,” it will enable a broader range of primary healthcare institutions and clinical experts to perform “digital-intelligent” minimally invasive surgeries. In September 2024, the Rossum Qingtian® Electrically Controlled Elastic Traction System also obtained the Product Registration Certificate for Innovative Medical Devices from the Beijing Medical Products Administration, becoming a typical case of translating innovation from the concept of medical-engineering convergence into tangible product innovation. Thus, the initial framework of Rossum Robot’s intelligent surgical solutions has begun to take shape: “Tiangong Creates All Things, Wanxiang Renews Everything, Lighthouse Provides Guidance, and Qingtian Spans the Seas.” Rossum Robot is committed to providing more intelligent solutions for orthopedic clinical practice through technological and product innovation, thereby enhancing health and well-being through scientific and technological advancement.

Rossum Robot Product Matrix

Dr. Wang Yu, Founder of Rossum RobotStatement: We extend our sincere gratitude to all investors in this round for their recognition and support of Rossum Robot, and we also thank WinX Capital for its full cooperation. Leveraging a robust innovation pathway that integrates medicine and engineering, Rossum Robot aims to become an internationally competitive provider of intelligent medical products and services. This year, Rossum Robot has launched several blockbuster products, initiated nationwide product promotion in collaboration with partners, and continued to advance the development of new indications as well as product iteration and optimization. In the future, Rossum Robot will remain true to its original aspiration, continuing to develop practical surgical robots that empower physicians to provide better patient care, while promoting the evolution of surgical treatment towards minimally invasive and intelligent approaches. We will persist in pioneering original innovations in cutting-edge technologies,立足 China with a global perspective, bringing Chinese-created intelligent surgical robots to the world stage. We firmly believe that the future of surgical robots is vast and promising; although the journey ahead is challenging and long, we will remain steadfast in our mission and strive forward with determination.

Zhu Fangwen, Partner at Shoucheng CapitalThe Beijing Robotics Industry Fund, as the lead investor in this round, expressed optimism about the long-term value of surgical robots in enhancing patient care experiences, reducing medical costs, and alleviating the societal burden of healthcare. It also highlighted the development potential of Rossum Robot in the field of orthopedic robotics. Rossum Robot’s reduction robot, built upon deep integration of medicine and engineering, targets high-difficulty pelvic fractures and represents a genuine international original innovation. The Robotics Fund will continue to support the intelligent upgrading and expansion of indications for Rossum Robot’s products, benefiting more patients and thereby contributing to the high-quality development of Beijing’s medical robotics industry.

Wang Jinghua, Managing Partner of Medtronic China FundStatement: Pelvic fracture reduction is a global challenge. Leveraging its exceptional capabilities in medical-engineering convergence, Rossum Robot has independently developed an intelligent fracture reduction robot. This innovation effectively addresses the lack of reduction functions in existing orthopedic surgical robots, enhances the therapeutic standards for closed reduction of pelvic fractures, advances the intelligence level of orthopedic surgical robots in China, and fills a research gap in this field. We firmly believe that digitalization and intelligence are inevitable trends in the future development of medical technology and essential pathways to improving the efficiency and quality of healthcare services. In the future, we will spare no effort to support the rapid growth of enterprises, with the expectation that their products will benefit more patients.

Shunxi Venture CapitalStatement: The Beijing Pharmaceutical and Health Industry Fund, aligned with Beijing’s industrial strategic layout, acknowledges that the adoption of robots as surgical tools has become an irreversible trend, with surgical robots continuing to iterate toward greater automation. There is a significant unmet clinical need in the treatment of pelvic fractures. Rossum Robot’s products, resulting from deep integration of medicine and engineering, hold the promise of making minimally invasive treatment for pelvic fractures a standard procedure, thereby enhancing clinical care standards and delivering clear patient benefits. This co-investment with the Robotics Fund signifies strong endorsement of the company. The Pharmaceutical and Health Industry Fund will continue to support the development of technology-driven innovative enterprises in Beijing, empowering their high-quality growth.

Teng Yuhang, Executive Partner at GTJA Investment GroupStatement: Global orthopedic surgery is undergoing a digital and intelligent transformation, with frontier technologies such as AI and robotics offering significant opportunities to empower orthopedic procedures. Starting from pelvic trauma and leveraging over a decade of deep integration between medicine and engineering, Rossum Robot has independently developed and established a digital product portfolio covering the treatment of complex orthopedic diseases. This empowers clinicians to perform complex minimally invasive surgeries, thereby benefiting patients. We look forward to the full market launch of innovative products such as reduction robots and bedside robots made by Chinese intelligent manufacturing, enabling patients in China and around the world to access high-quality healthcare.

Dr. Zou Guowen, Founding Partner of WinX CapitalStatement: We are honored to serve Rossum Robot, a high-quality enterprise with strong core competitiveness and significant growth potential. Driven by population aging, favorable national policies, the application of deep learning algorithms, and upgrades in mechanical-assisted hardware, both the demand for and supply of surgical robots are rising in tandem, leading to a continuous increase in market penetration. Rossum Robot has realized the vision of “entrusting the most challenging procedures to robots,” which represents an inevitable trend in the development of surgical robotics. This financing round has received joint support from two major industrial funds in Beijing, along with endorsements from top-tier international industrial partners and leading domestic market-oriented institutions, fully demonstrating widespread recognition of Rossum Robot’s products and technology across various sectors.

Beijing Rossum Robot Technology Co., Ltd., established in September 2017, has been honored with titles such as National High-Tech Enterprise, Specialized and Sophisticated “Little Giant” Enterprise, Technology-Based Small and Medium-sized Enterprise, Zhongguancun High-Tech Enterprise, and Zhongguancun Frontier Technology Enterprise. The company is dedicated to innovating intelligent digital technologies for medical robotics, enhancing health and well-being through technological advancement.

Driven by critical clinical needs, the company leverages digital intelligence to “replicate” the expertise of clinical specialists, developing globally leading intelligent orthopedic surgical robots and advancing the automation and intelligence of surgical robotics.

Beijing Robotics Industry Development Investment FundThe Beijing Robotics Industry Development Investment Fund was established in late 2023 as one of the first batch of municipal-level industrial investment funds, implementing the strategic deployments of the Beijing Municipal Party Committee and Municipal Government. With a total scale of RMB 10 billion, the fund is jointly managed by Jingguorui Fund and Shoucheng Capital, the equity investment platform under Shougang Fund. The mission of the Robotics Fund is to identify and empower a cohort of high-quality enterprises with genuine innovation and robust technologies to establish and develop in Beijing, promote the clustering of related industry chain enterprises in the city, support the construction of a complete industrial system encompassing product R&D, industrialization, and application ecosystems, and help build Beijing’s new engine for new quality productive forces.

In 2016, the Medtronic China Fund was officially established, focusing on several diseases with significant impact on public health in China and their clinical solutions. The fund primarily invests in early-stage domestic medical technology startups in China, while also investing in and accelerating overseas innovative technologies that align with the needs of the Chinese market.

In April 2023, Medtronic announced the launch of a new venture capital fund focused on the Chinese market: the Medtronic China Fund II, the second venture capital fund established in China. The fund will prioritize healthcare technology innovation companies in their early to mid-stage development, delving deeply into frontier medical technologies such as digital health, artificial intelligence, and robotics. It will invest in diagnostic and therapeutic products related to various major diseases, including cardiovascular, neurological, and oncological conditions.

The Beijing Pharmaceutical and Health Industry Investment Fund is the largest among the municipal-level industrial investment funds established in Beijing in 2023, with Shunxi Venture Capital serving as its fund manager. The fund implements the strategic deployments of the Beijing Municipal Committee of the Communist Party of China and the Beijing Municipal People’s Government by supporting original projects in research, pilot-scale trials, or scaled-up production; introducing a batch of high-quality major innovative domestic and international products to establish operations in Beijing; continuously expanding the scale of the city’s pharmaceutical and health industry; and building a globally competitive hub for the pharmaceutical and health industries.

Founded in Shenzhen in 2001, GTJA Investment Group pioneered the “thematic industry investment” model within the sector. Focusing on investments in the healthcare and medical industry, the firm is led by strategic equity investments and covers all investment stages, including venture capital (VC), private equity (PE), pre-IPO, and mergers and acquisitions (M&A). With one of the few professional investment teams in China deeply focused on the healthcare and medical track, it has built an investment ecosystem platform for the healthcare industry, striving to become a globally influential healthcare investment institution.

GTJA Investment Group manages assets exceeding RMB 22 billion, with 35 healthcare-focused funds. It has invested in over 110 healthcare companies and facilitated the successful IPOs of 37 enterprises, including Mindray Medical, United Imaging Healthcare, and Akeso Bio. With a China-based, globally-oriented strategy, GTJA Investment Group has established operational centers in Shenzhen, Shanghai, Beijing, and Hong Kong. It is committed to investing in outstanding healthcare companies worldwide, creating new development opportunities for global capital and medical enterprises, and helping entrepreneurs build great companies.

WinX Capital is a leading investment bank in China’s healthcare industry, headquartered in Beijing and Shanghai, with offices in Shenzhen and Hangzhou. It has received numerous accolades, including Qimingpian’s “No. 1 Financial Advisor in the Healthcare Sector for 2024,” First New Voice’s “No. 1 Financial Advisory Firm in the Healthcare Sector for 2022 and 2023,” and VCBeat’s “Annual Healthcare Financial Advisor” as part of the “Top 100 Future Healthcare Companies (2022–2024).”